SAHPRA clarifies the benefits and risks of medroxyprogesterone acetate

News Healthcare & Pharma Guidance

Date: 17th Jan, 2025 Source: South African Health Products Regulatory Authority (SAHPRA) Country: South Africa Original Source

Brief

On 17/01/2025, the South African Health Products Regulatory Authority (SAHPRA) issued an update regarding SAHPRA clarifies the benefits and risks of medroxyprogesterone acetate. The update informs that the product information of MPA-containing products will be amended to include the potential risk of meningioma, a benign brain tumour, after two epidemiological studies observed an increased risk with prolonged use of MPA.

This content is restricted.

Highlights content goes here...

This content is restricted.

South African Health Products Regulatory Authority (SAHPRA)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

SAHPRA clarifies the benefits and risks of medroxyprogesterone acetate

Brief

South African Health Products Regulatory Authority (SAHPRA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

SAHPRA clarifies the benefits and risks of medroxyprogesterone acetate

Brief

South African Health Products Regulatory Authority (SAHPRA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.